苯丙酮尿症的研究进展
Research Progress on Phenylketonuria
DOI: 10.12677/HJBM.2023.133038, PDF,    科研立项经费支持
作者: 王 杰, 张少伟, 谢欣茹, 任钊锐, 王加政, 常嘉秀, 曹广祥, 付加芳：山东第一医科大学(山东省医学科学院)生物医学科学学院，山东 济南
关键词: 苯丙酮尿症；单基因遗传病；遗传方式；预防与治疗；Phenylketonuria； Single-Gene Genetic Disease； Genetic Mode； Prevention and Treatment
摘要: 苯丙酮尿症(PKU)又称高苯丙氨酸血症，是常见的单基因遗传病，是一种由功能性苯丙氨酸羟化酶(PAH)缺乏引起的先天性代谢障碍，导致患者血液和器官中苯丙氨酸(Phe)的积累。患者会出现严重的发育迟缓、神经功能缺陷和行为异常等特征。苯丙酮尿症早期筛查，能够让更多的患儿得到早期诊断，进而更早地接受治疗，最大程度上减轻苯丙氨酸对神经系统的损害。本文综述了其遗传方式、病因机制、目前预防和治疗的措施。
Abstract: Phenylketonuria (PKU), also known as hyperphenylalaninemia, is a common single-gene genetic disease. It is a congenital metabolic disorder caused by the lack of functional phenylalanine hydroxylase (PAH), leading to the accumulation of phenylalanine (Phe) in the blood and organs of patients. Patients will have severe developmental retardation, neurological deficits and behavioral abnormalities. Early screening of phenylketonuria can enable more children to receive early diagnosis and treatment earlier, and minimize the damage of phenylalanine to the nervous system. This article reviews its genetic mode, pathogenesis, current prevention and treatment measures.
文章引用：王杰, 张少伟, 谢欣茹, 任钊锐, 王加政, 常嘉秀, 曹广祥, 付加芳. 苯丙酮尿症的研究进展[J]. 生物医学, 2023, 13(3): 326-333. https://doi.org/10.12677/HJBM.2023.133038

参考文献

[1] Yan, Y., Zhang, C., Jin, X., et al. (2019) Mutation Spectrum of PAH Gene in Phenylketonuria Patients in Northwest China: Identification of Twenty Novel Variants. Metabolic Brain Disease, 34, 733-745. [Google Scholar] [CrossRef] [PubMed]
[2] van Wegberg, A., MacDonald, A., Ahring, K., et al. (2017) The Complete European Guidelines on Phenylketonuria: Diagnosis and Treatment. Orphanet Journal of Rare Diseases, 12, Article No. 162. [Google Scholar] [CrossRef] [PubMed]
[3] Elhawary, N.A., AlJahdali, I.A., Abumansour, I.S., et al. (2022) Genetic Etiology and Clinical Challenges of Phenylketonuria. Human Genomics, 16, Article No. 22. [Google Scholar] [CrossRef] [PubMed]
[4] Blau, N., Shen, N. and Carducci, C. (2014) Molecular Genetics and Diagnosis of Phenylketonuria: State of the Art. Expert Review of Molecular Diagnostics, 14, 655-671. [Google Scholar] [CrossRef] [PubMed]
[5] Rovelli, V. and Longo, N. (2023) Phenylketonuria and the Brain. Molecular Genetics and Metabolism, 139, Article ID: 107583. [Google Scholar] [CrossRef] [PubMed]
[6] Hoeks, M.P., den Heijer, M. and Janssen, M.C. (2009) Adult Issues in Phenylketonuria. The Netherlands Journal of Medicine, 67, 2-7.
[7] Feldmann, R., Osterloh, J., Onon, S., et al. (2019) Neurocognitive Functioning in Adults with Phenylketonuria: Report of a 10-Year Follow-Up. Molecular Genetics and Metabolism, 126, 246-249. [Google Scholar] [CrossRef] [PubMed]
[8] Dijkstra, A.M., van Vliet, N., van Vliet, D., et al. (2021) Correlations of Blood and Brain Biochemistry in Phenylketonuria: Results from the Pah-enu2 PKU Mouse. Molecular Genetics and Metabolism, 134, 250-256. [Google Scholar] [CrossRef] [PubMed]
[9] Blau, N. (2016) Genetics of Phenylketonuria: Then and Now. Human Mutation, 37, 508-515. [Google Scholar] [CrossRef] [PubMed]
[10] van Spronsen, F.J., Huijbregts, S.C., Bosch, A.M., et al. (2011) Cognitive, Neurophysiological, Neurological and Psychosocial Outcomes in Early-Treated PKU-Patients: A Start toward Standardized Outcome Measurement across Development. Molecular Genetics and Metabolism, 104, S45-S51. [Google Scholar] [CrossRef] [PubMed]
[11] Azevedo, S.C., Ferreira, A.M., Soares, G., et al. (2023) Predicting Factors of Neurodevelopmental Performance in Children with Phenylketonuria. American Journal of Medical Genetics Part A, 191, 1525-1529. [Google Scholar] [CrossRef] [PubMed]
[12] Grant, M.L., Jurecki, E.R., McCandless, S.E., et al. (2023) Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria. The Journal of Pediatrics, 260, Article ID: 113526. [Google Scholar] [CrossRef] [PubMed]
[13] 任丹, 于蕾, 李航, 等. 成人苯丙酮尿症1例家系分析并文献复习[J]. 卒中与神经疾病, 2023, 30(2): 204-205.
[14] Grohmann-Held, K., Burgard, P., Baerwald, C., et al. (2022) Impact of Pregnancy Planning and Preconceptual Dietary Training on Metabolic Control and Offspring’s Outcome in Phenylketonuria. Journal of Inherited Metabolic Disease, 45, 1070-1081. [Google Scholar] [CrossRef] [PubMed]
[15] De Giorgi, A., Nardecchia, F., Manti, F., et al. (2023) Neuroimaging in Early-Treated Phenylketonuria Patients and Clinical Outcome: A Systematic Review. Molecular Genetics and Metabolism, 139, Article ID: 107588. [Google Scholar] [CrossRef] [PubMed]
[16] Rohr, F.J., Doherty, L.B., Waisbren, S.E., et al. (1987) New England Maternal PKU Project: Prospective Study of Untreated and Treated Pregnancies and Their Outcomes. The Journal of Pediatrics, 110, 391-398. [Google Scholar] [CrossRef] 
[17] Drogari, E., Smith, I., Beasley, M., et al. (1987) Timing of Strict Diet in Relation to Fetal Damage in Maternal Phenylketonuria. An International Collaborative Study by the MRC/DHSS Phenylketonuria Register. The Lancet, 2, 927-930. [Google Scholar] [CrossRef] 
[18] Jervis, G.A. (1953) Phenylpyruvic Oligophrenia Deficiency of Phenylalanine-Oxidizing System. Proceedings of the Society for Experimental Biology and Medicine, 82, 514-515.
[19] van Spronsen, F.J., Blau, N., Harding, C., et al. (2021) Phenylketonuria. Nature Reviews Disease Primers, 7, Article No. 36. [Google Scholar] [CrossRef] [PubMed]
[20] (2021) Phenylketonuria. Nature Reviews Disease Primers, 7, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[21] Lichter-Konecki, U. and Vockley, J. (2019) Phenylketonuria: Current Treatments and Future Developments. Drugs, 79, 495-500. [Google Scholar] [CrossRef] [PubMed]
[22] Manti, F., Caviglia, S., Cazzorla, C., et al. (2022) Expert Opinion of an Italian Working Group on the Assessment of Cognitive, Psychological, and Neurological Outcomes in Pediatric, Adolescent, and Adult Patients with Phenylketonuria. Orphanet Journal of Rare Diseases, 17, Article No. 443. [Google Scholar] [CrossRef] [PubMed]
[23] Zori, R., Ahring, K., Burton, B., et al. (2019) Long-Term Comparative Effectiveness of Pegvaliase versus Standard of Care Comparators in Adults with Phenylketonuria. Molecular Genetics and Metabolism, 128, 92-101. [Google Scholar] [CrossRef] [PubMed]
[24] Hanley, W.B. (2004) Adult Phenylketonuria. The American Journal of Medicine, 117, 590-595. [Google Scholar] [CrossRef] [PubMed]
[25] Walter, J.H. and White, F.J. (2004) Blood Phenylalanine Control in Adolescents with Phenylketonuria. International Journal of Adolescent Medicine and Health, 16, 41-45. [Google Scholar] [CrossRef] 
[26] Evers, R., van Wegberg, A., MacDonald, A., et al. (2022) Dietary Liberalization in Tetrahydrobiopterin-Treated PKU Patients: Does It Improve Outcomes? Nutrients, 14, Article No. 3874. [Google Scholar] [CrossRef] [PubMed]
[27] Grisch-Chan, H.M., Schwank, G., Harding, C.O., et al. (2019) State-of-the-Art 2019 on Gene Therapy for Phenylketonuria. Human Gene Therapy, 30, 1274-1283. [Google Scholar] [CrossRef] [PubMed]
[28] Puurunen, M.K., Vockley, J., Searle, S.L., et al. (2021) Safety and Pharmacodynamics of an Engineered E. coli Nissle for the Treatment of Phenylketonuria: A First-in-Human Phase 1/2a Study. Nature Metabolism, 3, 1125-1132. [Google Scholar] [CrossRef] [PubMed]
[29] Charbonneau, M.R., Denney, W.S., Horvath, N.G., et al. (2021) Development of a Mechanistic Model to Predict Synthetic Biotic Activity in Healthy Volunteers and Patients with Phenylketonuria. Communications Biology, 4, Article No. 898. [Google Scholar] [CrossRef] [PubMed]
[30] Isabella, V.M., Ha, B.N., Castillo, M.J., et al. (2018) Development of a Synthetic Live Bacterial Therapeutic for the Human Metabolic Disease Phenylketonuria. Nature Biotechnology, 36, 857-864. [Google Scholar] [CrossRef] [PubMed]

为你推荐